PPARδ agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-07-28. Anything still debated is marked as such rather than presented as settled.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic PPARδ agonist | Not a steroid or a selective androgen receptor modulator. |
| Common synonyms | Cardarine, GW501516, GW-501516, endurobol | Names vary by supplier and literature source. |
| Appearance | White to off-white powder | Consistent with many small-molecule research chemicals. |
| Solubility | Low in water; soluble in DMSO and ethanol | Often prepared in organic solvent for laboratory work. |
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid and energy metabolism. |
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Clinical psychologists engage in a wide range of activities. Some focus solely on research into the assessment, treatment, or cause of mental illness and related conditions. Some teach, whether in a medical school or hospital setting, or in an academic department (e.g., psychology department) at an institution of higher education. The majority of clinical psychologists engage in some form of clinical practice, with professional services including psychological assessment, provision of psychotherapy, development and administration of clinical programs, and forensics (e.g., providing expert testimony in a legal proceeding). In clinical practice, clinical psychologists may work with individuals, couples, families, or groups in a variety of settings, including private practices, hospitals, mental health organizations, schools, businesses, and non-profit agencies. Clinical psychologists who provide clinical services may also choose to specialize. Some specializations are codified and credentialed by regulatory agencies within the country of practice. In the United States, such specializations are credentialed by the American Board of Professional Psychology (ABPP).
=== Factors === There are some factors that are closely related to the selectivity property of antimicrobial peptides, among which the cationic property contributes most. Since the surface of the bacterial membranes is more negatively charged than mammalian cells, antimicrobial peptides will show different affinities towards the bacterial membranes and mammalian cell membranes. In addition, there are also other factors that will affect the selectivity. It's well known that cholesterol is normally widely distributed in the mammalian cell membranes as a membrane stabilizing agent but absent in bacterial cell membranes (except when sequestered by H. pylori); and the presence of these cholesterols will also generally reduce the activities of the antimicrobial peptides, due either to stabilization of the lipid bilayer or to interactions between cholesterol and the peptide. So the cholesterol in mammalian cells will protect the cells from attack by the antimicrobial peptides. Besides, the transmembrane potential is well known to affect peptide-lipid interactions. There's an inside-negative transmembrane potential existing from the outer leaflet to the inner leaflet of the cell membranes and this inside-negative transmembrane potential will facilitate membrane permeabilization probably by facilitating the insertion of positively charged peptides into membranes. By comparison, the transmembrane potential of bacterial cells is more negative than that of normal mammalian cells, so bacterial membrane will be prone to be attacked by the positively charged antimicrobial peptides.
Oxycodone was allegedly chosen over other common opiates for this product because it had been shown to produce less sedation at equianalgesic doses compared to morphine, hydromorphone (Dilaudid), and hydrocodone (Dicodid). During Operation Himmler, Skophedal was also reportedly injected in massive overdose into the prisoners dressed in Polish Army uniforms in the staged incident on 1 September 1939 which opened the Second World War. The personal notes of Adolf Hitler's physician, Theodor Morell, indicate Hitler received repeated injections of "Eukodal" (oxycodone; produced by Merck) and Scophedal, as well as Dolantin (pethidine), codeine, and morphine less frequently; oxycodone could not be obtained after late January 1945. In the United States, the Controlled Substances Act (CSA) was passed by the United States Congress and signed into law by President Richard Nixon on 27 October 1970. The passing of the CSA resulted in all products containing oxycodone being classified as a Schedule II controlled substance. In the early 1990s, Purdue Pharma, a privately held company based in Stamford, Connecticut, developed a controlled-release version of oxycodone: the prescription painkiller OxyContin ("contin" being short for "continuous", reflecting a longer duration of pain relief). It was approved by the FDA in 1995 after no long-term studies and no assessment of its addictive capabilities. David Kessler, the FDA commissioner at the time, later said of the approval of OxyContin: "No doubt it was a mistake.
19 August – Kate Osborne, the MP for Jarrow and Gateshead East, is being investigated by the Independent Parliamentary Standards Authority for her spending on travel and subsistence costs, as well as "miscellaneous costs and financial assistance" following an operation. 20 August – James Harding, the BBC's former director of news, says the broadcaster should be protected from "political interference" following comments by Culture Secretary Lisa Nandy earlier in the year, when she appeared to call for the resignation of director-general Tim Davie. Former Conservative MP Sarah Atherton leaves the party, describing it as "impotent" and something that "no longer aligns" with her "values or ideology", and announces plans to stand in the 2026 Senedd election. 22 August – MSP Jeremy Balfour resigns from the Scottish Conservatives, saying the party has "fallen into the trap of reactionary politics" under the leadership of Russell Findlay. Dame Andrea Jenkyns, Zia Yusuf, Gawain Towler, Darren Grimes, Dan Barker and Paul Nuttall join Reform UK's governing board. 23 August – Nigel Farage tells The Times that a Reform government would introduce an Illegal Migration (Mass Deportation) Bill that would cost the UK £10bn to implement. 25 August – Richard Tice, Reform UK's energy spokesman, says the party would look at the potential of fracking if in government. 26 August – Safeguarding Minister Jess Phillips tells BBC News that the screening tool used to decide which domestic abuse victims get urgent support "doesn't work".
Sources: en.wikipedia.org
This led in 1976 to the development and introduction of Progestasert, a progesterone-containing product and the first progestogen-containing IUD. Unfortunately, the product had various problems that limited its use. These included a short duration of efficacy of only one year, a high cost, a relatively high 2.9% failure rate, a lack of protection against ectopic pregnancy, and difficult and sometimes painful insertions that could necessitate use of a local anesthetic or analgesic. As a result of these issues, Progestasert never became widely used, and was discontinued in 2001. It was used mostly in the United States and France while it was marketed.
In January 1943, Colonel David Stirling was captured in Tunisia and Paddy Mayne replaced him as commander. In April 1943, the 1st SAS was reorganised into the Special Raiding Squadron under Mayne's command and the Special Boat Section was placed under the command of George Jellicoe. The Special Raiding Squadron fought in Sicily and Italy along with the 2nd SAS, which had been formed in North Africa in 1943 in part by the renaming of the Small Scale Raiding Force under the command of Bill Stirling (brother of David). The Special Boat Squadron fought in the Aegean Islands and Dodecanese until the end of the war. In 1944 the SAS Brigade was formed. The unit was formed from:
NAPQI, also known as NAPBQI or N-acetyl-p-benzoquinone imine, is a toxic byproduct produced during the xenobiotic metabolism of the analgesic paracetamol (acetaminophen). It is normally produced only in small amounts, and then almost immediately detoxified in the liver. However, under some conditions in which NAPQI is not effectively detoxified, usually in the case of paracetamol overdose, it causes severe damage to the liver. This becomes apparent 3–4 days after ingestion and may result in death from fulminant liver failure several days after the overdose.
Sources: en.wikipedia.org
== History == Oxymorphone was first developed in Germany in 1914, and patented in the US by Endo Pharmaceuticals in 1955. It was introduced in the United States in January 1959 and other countries around the same time.
=== Water treatment === The "PolyGlu PGα21Ca" water flocculant, based on a mixture of gamma PGA, calcium sulfate, and calcium carbonate, is used by the International Organization for Migration to treat water for refugees. G-PGA covalently incorporated into microfiltration membranes via attachment to their membrane pore surfaces exhibited super-high heavy metal sorption ability. G-PGA was found to bind and efficiently remove 99.8% of lead ions from water via a suitable low-pressure ultrafiltration technique.
==== Mesocorticolimbic pathway ==== Understanding the pathways in which drugs act and how drugs can alter those pathways is key when examining the biological basis of drug addiction. The reward pathway, known as the mesolimbic pathway, or its extension, the mesocorticolimbic pathway, is characterized by the interaction of several areas of the brain. Dopaminergic neurons in the ventral tegmental area (VTA) fire in response to cues that predict a reward and project to the nucleus accumbens through the mesolimbic pathway; nearly all addictive drugs increase dopamine release along this pathway, although they act on it by different routes. The nucleus accumbens, made up largely of GABAergic medium spiny neurons, is a principal target of these projections and is involved in learning conditioned responses to drug-associated cues, and in the growing sensitivity to those cues as addiction progresses. A further target is the prefrontal cortex, including the anterior cingulate and orbitofrontal cortices, which weighs competing information in determining whether a behavior is carried out and forms the associations between drug reward and environmental cues that give those cues their power. These cues are strong mediators of drug-seeking behavior and can trigger relapse even after months or years of abstinence.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.
It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.
No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.